Adjuvant denosumab improves disease-free survival for postmenopausal women with early

[News]

Adding denosumab to adjuvant aromatase inhibitor therapy improved disease-free survival for postmenopausal patients with early-stage, hormone receptor (HR)-positive breast cancer, according to results from the phase III ABCSG-18 clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12.

More... (http://www.news-medical.net/news/20151209/Adjuvant-denosumab-improves-disease-free-survival-for-postmenopausal-women-with-early-stage-HR2b-breast-cancer.aspx)